News & Views | Published:

IMMUNOTHERAPY

Programmable bacteria as cancer therapy

Quorum-sensing bacteria can deliver a nanobody targeting the ‘don’t eat me’ ligand CD47 to tumors that results in systemic anti-tumor immunity-induced regression in mice.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Starnes, C. O. Nature 357, 11–12 (1992).

  2. 2.

    Chowdhury, S. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0498-z (2019).

  3. 3.

    Ingram, J. R., Schmidt, F. I. & Ploegh, H. L. Annu. Rev. Immunol. 36, 695–715 (2018).

  4. 4.

    Sockolosky, J. T. et al. Proc. Natl Acad. Sci. USA 113, E2646–E2654 (2016).

  5. 5.

    Jaiswal, S. et al. Cell 138, 271–285 (2009).

  6. 6.

    Weiskopf, K. Eur. J. Cancer 76, 100–109 (2017).

  7. 7.

    Weiskopf, K. et al. Science 341, 88–91 (2013).

  8. 8.

    Advani, R. et al. N. Engl. J. Med. 379, 1711–1721 (2018).

  9. 9.

    Ingram, J. R. et al. Proc. Natl Acad. Sci. USA 114, 10184–10189 (2017).

  10. 10.

    Liu, X. et al. Nat. Med. 21, 1209–1215 (2015).

  11. 11.

    Xu, M. M. et al. Immunity 47, 363–373.e365 (2017).

  12. 12.

    Silva, D. A. et al. Nature 565, 186–191 (2019).

Download references

Author information

Correspondence to Stephanie K. Dougan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1: Inducing systemic anti-tumor immunity with quorum-sensing bacteria carrying nanobodies.